Alogliptindosage

Individualize the starting dosage based on the patient's current regimen. Given orally twice daily with food. Adjust the dosage based on effectiveness and tolerability while not exceeding the maximum recommended daily dosage of 25 mg alogliptin and 2000 mg metformin HCl. Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR). Do not use in patients with eGFR below 60 mL/min/1.73 m 2. KAZANO may need to be discontinued at time of, or prior to, iodinated contrast imaging procedures.

2.1 Recommended

Dosage Individualize the starting dosage of KAZANO based on the patient's current regimen. KAZANO should be taken orally twice daily with food with gradual dose escalation to reduce the gastrointestinal (GI) side effects due to metformin. Do not split tablets. Adjust the dosage based on effectiveness and tolerability while not exceeding the maximum recommended daily dose of 25 mg alogliptin and 2000 mg metformin hydrochloride (HCl).

2.2 Recommendations for

Use in Renal Impairment Assess renal function prior to initiation of KAZANO and periodically thereafter. KAZANO is contraindicated in patients with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m 2. KAZANO is not recommended in patients with an eGFR between 30 and 59 mL/min/1.73 m 2 because these patients require a lower daily dosage of alogliptin than what is available in the fixed combination KAZANO product. Kazano requires no dose adjustment in patients with an eGFR of 60 mL/min/1.73 m 2 or greater.

2.3 Discontinuation for

Iodinated Contrast Imaging Procedures Discontinue KAZANO at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m 2; in patients with a history of liver disease, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure; restart KAZANO if renal function is stable.